R&D News | pharmaphorum

News

EU invests €30m to fight antimicrobial resistance

The EU has pledged €30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.

News

Gilead strikes again, penning $5bn deal to buy Tubulis

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

News

AI giant Anthropic buys Coefficient Bio for $400m

Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio.

News

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

Amgen scientists working in the lab, one woman and one man

Amgen scores with new thyroid eye disease formulation

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

News

Ambrosia's sweet $100m round, and other biofinancings

Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.

EU invests €30m to fight antimicrobial resistance

Gilead strikes again, penning $5bn deal to buy Tubulis

AI giant Anthropic buys Coefficient Bio for $400m

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Amgen scores with new thyroid eye disease formulation

Ambrosia's sweet $100m round, and other biofinancings

GSK to file Jemperli for rectal cancer after phase 3 readout

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks